X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (80) 80
oncology (61) 61
female (60) 60
male (58) 58
middle aged (56) 56
index medicus (53) 53
aged (49) 49
chemotherapy (45) 45
lung neoplasms - drug therapy (44) 44
adult (41) 41
carcinoma, non-small-cell lung - drug therapy (38) 38
lung neoplasms - pathology (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
cancer (28) 28
carcinoma, non-small-cell lung - pathology (28) 28
neoplasm staging (27) 27
treatment outcome (26) 26
lung cancer (25) 25
aged, 80 and over (22) 22
lung neoplasms - mortality (22) 22
carcinoma, non-small-cell lung - mortality (21) 21
therapy (19) 19
disease-free survival (18) 18
non-small cell lung cancer (18) 18
lung cancer, non-small cell (16) 16
respiratory system (16) 16
double-blind method (15) 15
survival rate (15) 15
care and treatment (14) 14
cisplatin (14) 14
survival (14) 14
cisplatin - administration & dosage (13) 13
docetaxel (13) 13
poland (13) 13
prognosis (13) 13
antineoplastic agents - therapeutic use (12) 12
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
hematology, oncology and palliative medicine (12) 12
proportional hazards models (12) 12
tumors (12) 12
gefitinib (11) 11
survival analysis (11) 11
vinblastine - analogs & derivatives (11) 11
adenocarcinoma - drug therapy (10) 10
diagnosis (10) 10
disease progression (10) 10
europe (10) 10
kaplan-meier estimate (10) 10
metastasis (10) 10
non-small-cell lung cancer (10) 10
quality of life (10) 10
radiotherapy (10) 10
solid tumors (10) 10
trial (10) 10
vinblastine - administration & dosage (10) 10
antineoplastic agents (9) 9
carcinoma, non-small-cell lung - genetics (9) 9
erlotinib (9) 9
follow-up studies (9) 9
cancer therapies (8) 8
carboplatin (8) 8
carcinoma, non-small-cell lung - therapy (8) 8
clinical trials (8) 8
combination (8) 8
expression (8) 8
lung neoplasms - genetics (8) 8
multicenter (8) 8
mutation (8) 8
practice guidelines as topic (8) 8
research (8) 8
risk factors (8) 8
adenocarcinoma - mortality (7) 7
antimitotic agents (7) 7
antineoplastic agents - adverse effects (7) 7
drug therapy (7) 7
erlotinib hydrochloride (7) 7
gemcitabine (7) 7
lung neoplasms - diagnosis (7) 7
open-label (7) 7
paclitaxel - administration & dosage (7) 7
pulmonary/respiratory (7) 7
time factors (7) 7
adenocarcinoma - pathology (6) 6
analysis (6) 6
antineoplastic agents - administration & dosage (6) 6
carboplatin - administration & dosage (6) 6
carcinoma, non-small-cell lung - diagnosis (6) 6
carcinoma, non-small-cell lung - secondary (6) 6
carcinoma, squamous cell - drug therapy (6) 6
cell lung-cancer (6) 6
combined modality therapy (6) 6
efficacy (6) 6
growth-factor receptor (6) 6
lung neoplasms - therapy (6) 6
medical colleges (6) 6
nsclc (6) 6
placebos (6) 6
predictive value of tests (6) 6
prospective studies (6) 6
quality-of-life (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 143 - 155
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9699, pp. 1432 - 1440
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. 33 - 42
Summary Background Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed that the addition of cetuximab to first-line chemotherapy... 
Hematology, Oncology and Palliative Medicine | BREAST-CANCER | BIOMARKERS | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | PROTEIN EXPRESSION | IN-SITU HYBRIDIZATION | CARCINOMAS | GENE AMPLIFICATION | ESTROGEN-RECEPTOR | III TRIAL | Immunohistochemistry | Lung Neoplasms - drug therapy | Up-Regulation | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Patient Selection | Young Adult | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Vinblastine - analogs & derivatives | Aged, 80 and over | Biomarkers, Tumor - metabolism | Brazil | Adult | Female | Biomarkers, Tumor - antagonists & inhibitors | Cetuximab | Odds Ratio | Republic of Korea | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - enzymology | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Care and treatment | Patient outcomes | Oncology, Experimental | Research | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Cancer patients | Chemotherapy | Product development | Tumors | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 59 - 68
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9674, pp. 1525 - 1531
Summary Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in... 
Internal Medicine | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | THERAPY | CISPLATIN | COMBINATION | GEMCITABINE | ERLOTINIB | PACLITAXEL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptor, Epidermal Growth Factor - drug effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Aged, 80 and over | Adult | Female | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Proportional Hazards Models | Survival Rate | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Chemotherapy | Research | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Cancer | Drugs | Studies | Data analysis | Lung cancer | Acne | Monoclonal antibodies | Clinical medicine | Kinases | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2018, Volume 379, Issue 23, pp. 2220 - 2229
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2013, Volume 31, Issue 32, pp. 4105 - 4114
Journal Article
Journal Article